Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia

Ron L. H. Handels*, Anders Wimo, Richard Dodel, Milica G. Kramberger, Pieter Jelle Visser, Jose Luis Molinuevo, Frans R. J. Verhey, Bengt Winblad

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1477-1487
Number of pages11
JournalJournal of Alzheimer's Disease
Volume60
Issue number4
DOIs
Publication statusPublished - 7 Nov 2017

Keywords

  • Alzheimer's disease
  • cerebrospinal fluid
  • cost-utility
  • economic evaluation
  • mild cognitive impairment
  • prognosis
  • risk
  • ASSOCIATION WORKGROUPS
  • DIAGNOSTIC GUIDELINES
  • MODIFYING TREATMENT
  • NATIONAL INSTITUTE
  • RECOMMENDATIONS
  • CRITERIA
  • IMPACT

Cite this